Xiao-Xia Niu
Overview
Explore the profile of Xiao-Xia Niu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li S, Niu X, Liu J, Su M, Li Q, Wang C, et al.
Eur J Gastroenterol Hepatol
. 2025 Feb;
PMID: 39976005
Objectives: The role of the gut-liver axis in liver cirrhosis is becoming increasingly recognized. We investigated the fecal microbiome in patients with liver cirrhosis and its potential function as a...
2.
Xiong Y, Wang J, Niu X, Fu Y, Wang K, Wang C, et al.
Front Pharmacol
. 2023 Mar;
14:1071709.
PMID: 36874016
Drug-induced liver injury (DILI) is a potentially serious adverse drug reaction. Due to the lack of definite etiology, specific clinical manifestations, and diagnostic methods, its prediction and diagnosis are challenging....
3.
4.
Deng Y, Wang C, Niu X, Ji D
Hepatology
. 2022 Jan;
75(5):1349-1351.
PMID: 35098558
No abstract available.
5.
Li Z, Chen D, He Q, Li L, Zhou G, Fu Y, et al.
Front Pharmacol
. 2021 Sep;
12:734090.
PMID: 34483945
Currently, there are no satisfactory noninvasive methods for the diagnosis of fibrosis in patients with chronic drug-induced liver injury (DILI). Our goal was to develop an algorithm to improve the...
6.
Ji D, Chen G, Niu X, Zhang M, Wang C, Shao Q, et al.
Metabol Open
. 2021 Apr;
10:100090.
PMID: 33889834
Background And Aim: The incidence of hepatocellular carcinoma (HCC) decreases significantly in chronic hepatitis C (CHC) patients with sustained virologic response (SVR) after pegylated-interferon plus ribavirin (PR) or direct-acting antiviral...
7.
Li Z, Li L, Niu X, Chen S, Fu Y, Wang C, et al.
Liver Int
. 2021 Jan;
41(6):1254-1264.
PMID: 33404182
Background And Aims: About 20% of patients receiving nucleos(t)ide analogues treatment experienced low-level viraemia (LLV), which is associated with progression of liver fibrosis and high risk of hepatocellular carcinoma. We...
8.
Ji D, Ji Y, Duan X, Li W, Sun Z, Song X, et al.
Oncotarget
. 2017 Jan;
8(8):12784-12791.
PMID: 28061463
The 2014-2015 Ebola epidemic was considered to be the largest and most complex outbreak, which caused 11,310 reported deaths. The epidemic disease can cause a mental health crisis, however, there...
9.
Ji D, Chen G, Wang C, Wang Y, Shao Q, Li B, et al.
Hepatol Int
. 2016 Jul;
10(5):789-98.
PMID: 27443347
Background: Treatment-experienced chronic hepatitis C (CHC) genotype (GT) 1b represents a major medical burden in China. We evaluate the efficacy, safety and cost-effectiveness of ribavirin (RBV)-free pan-oral direct-acting antivirals (DAAs)...
10.
Chen G, Wei L, Chen J, Duan Z, Dou X, Xie Q, et al.
PLoS One
. 2016 Jun;
11(6):e0155934.
PMID: 27276081
Background: Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We...